Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Patient reported dose adequacy in injectable opioid agonist treatment: the role of patient involvement in dose decision-making

FY 2018-19

Summary
Opioid use disorder (OUD) is a chronic condition where people sometimes continue using opioids despite negative consequences and potential risks, other times they might: engage into treatment, temporarily or permanently stop use (without treatment), or relapse into drug use. For people struggling with an OUD, the most effective care option is opioid agonist treatment (OAT). OAT usually involves prescribing an oral medication (e.g. methadone, buprenorphine, slow-release morphine) that blocks the physical need to use street opioids. Some patients still inject opioids even if OAT is available and will respond better to injectable opioid agonist treatment (iOAT), therefore reducing the harms, risks, and costs associated with criminalized and untreated street opioid (e.g. illicit heroin, fentanyl) use, such as fatal overdose. Research into oral OAT indicates that involving patients in dose decision-making improves the likelihood that each patient receives an adequate dose: a dose which is individualized, more effective at retaining the patient, and has a better chance of helping the patient reduce their use of street opioids. Dose adequacy is measured through a clinical questionnaire which asks the patient about their OUD symptoms (e.g. withdrawals, street opioid use) and their experience of the OAT dose (e.g. overmedication symptoms, reduced cravings). Since dose adequacy is associated with better outcomes in oral OAT, I will study dose adequacy in patients new to iOAT (about 350 patients). Furthermore, since involving the patient in dose decision-making plays the biggest role in improving dose adequacy (in oral OAT), I will measure this factor and examine its relationship with dose-adequacy in iOAT. This research will help inform and support effective provision of iOAT.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406588
Name
Beaumont Scott
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Patient reported dose adequacy in injectable opioid agonist treatment: the role of patient involvement in dose decision-making
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Addictions; Dose Adequacy; Health Care Delivery; Injectable Opioid Agonist Treatment; Opioid Agonist Treatment; Opioid Use Disorder; Patient-Centered Care; Patient-Reported Measures; Quantitative Methods; Shared Decision-Making
Abstract
Opioid use disorder (OUD) is a chronic condition where people sometimes continue using opioids despite negative consequences and potential risks, other times they might: engage into treatment, temporarily or permanently stop use (without treatment), or relapse into drug use. For people struggling with an OUD, the most effective care option is opioid agonist treatment (OAT). OAT usually involves prescribing an oral medication (e.g. methadone, buprenorphine, slow-release morphine) that blocks the physical need to use street opioids. Some patients still inject opioids even if OAT is available and will respond better to injectable opioid agonist treatment (iOAT), therefore reducing the harms, risks, and costs associated with criminalized and untreated street opioid (e.g. illicit heroin, fentanyl) use, such as fatal overdose. Research into oral OAT indicates that involving patients in dose decision-making improves the likelihood that each patient receives an adequate dose: a dose which is individualized, more effective at retaining the patient, and has a better chance of helping the patient reduce their use of street opioids. Dose adequacy is measured through a clinical questionnaire which asks the patient about their OUD symptoms (e.g. withdrawals, street opioid use) and their experience of the OAT dose (e.g. overmedication symptoms, reduced cravings). Since dose adequacy is associated with better outcomes in oral OAT, I will study dose adequacy in patients new to iOAT (about 350 patients). Furthermore, since involving the patient in dose decision-making plays the biggest role in improving dose adequacy (in oral OAT), I will measure this factor and examine its relationship with dose-adequacy in iOAT. This research will help inform and support effective provision of iOAT.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Beaumont, Scott
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~